Additive effect of Tadalafil and Simvastatin on monocrotaline-induced pulmonary hypertension rats

References

• Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–117.
   PubMed Web of Science ®Google Scholar
• Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361:1533–1544.
   PubMed Web of Science ®Google Scholar
• European Society of Cardiology and the European Respiratory Society. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009;30:2493–510.
   PubMed Web of Science ®Google Scholar
• Provencher S, Sitbon O, Humbert M, Cabrol S, Jais X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27:589–595.
   PubMed Web of Science ®Google Scholar
• Falk JA, Philip KJ, Schwarz ER. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag. 2010;6:273–280.
   PubMedGoogle Scholar
• Sawamura F, Kato M, Fujita K, Nakazawa T, Beardsworth A. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009;111:235–243.
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z; . Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group, Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95–112.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002;166:1403–1408.
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, . Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;291:L668–676.
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ . Simvastatin as a treatment for pulmonary hypertension trial. AM J Respir Crit Care. 2010;181: 1106–1113.
   PubMed Web of Science ®Google Scholar
• Howell K, Preston RJ, McLoughlin P. Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol. 2003;547:133–145.
   PubMed Web of Science ®Google Scholar
• Dumitrascu R, Koebrich S, Dony E, Weissmann N, Savai R, Pullamsetti SS, . Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm Med. 2008;8:25.
   PubMedGoogle Scholar
• Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272:31725–31729.
   PubMed Web of Science ®Google Scholar
• Yen CH, Leu S, Lin YC, Kao YH, Chang LT, Chua S, . Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. Cardiovasc Pharmacol. 2010;55:574–584.
   PubMed Web of Science ®Google Scholar
• Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 2003;107:3230–3235.
   PubMed Web of Science ®Google Scholar
• Li B, Yang L, Shen J, Wang C, Jiang Z. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg. 2007;105:1034–1041.
   PubMed Web of Science ®Google Scholar
• Hsu HH, Ko WJ, Hsu JY, Chen JS, Lee YC, Lai IR, . Simvastatin ameliorates established pulmonary hypertension through a heme oxygease-1 dependent pathway in rats. Respir Res. 2009;10:32.
   PubMedGoogle Scholar
• Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, . Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med. 2011;183:50–58.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275–285.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, . Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136:678–687.
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, . Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151: 1628–1631.
   PubMed Web of Science ®Google Scholar
• Yoshio T, Masuyama JI, Kohda N, Hirata D, Sato H, Iwamoto M, . Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol. 1997;24:489–495.
   PubMed Web of Science ®Google Scholar
• Golembeski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest. 2005;128:572S–573S.
   PubMed Web of Science ®Google Scholar
• Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 over expression induces pulmonary hypertension. Circ Res. 2009;104:236–244.
   PubMed Web of Science ®Google Scholar
• Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.
   PubMed Web of Science ®Google Scholar